1. Pink Sheet
  3. >>US FDA

Shutdown Prep: US FDA Updates Plan To Furlough More Employees

 
• By Derrick Gingery

New FY 2024 plans would retain only 74% of staff, compared to the original, which retained 81%, but still increase the number of workers retained because of user fees.

government shutdown clock
If the government shuts down, sponsors may not notice service level differences for a few weeks. • Source: Shutterstock

Updated plans indicate the US Food and Drug Administration would furlough substantially more employees than thought at the beginning of fiscal year 2024, potentially adding to the stress on services should the government shut down.

Federal agency budgets have been running on a continuing resolution since FY 2024 began on 1 October 2023. FDA funding...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

US FDA To Advisory Committee Industry Reps: Don’t Talk Too Much

 
• By Sue Sutter

Nonvoting industry representative’s presence at Pediatric Advisory Committee meeting was required by statute, the agency said, a de facto acknowledgement that an April directive precluding industry reps from sitting on advisory committees has had little practical effect.

Senate Appropriators Give US FDA More Non-User Fee Funds Than House

 
• By Sarah Karlin-Smith

US FDA would receive more funding for fiscal year 2026 in the Senate appropriations bill than its House counterpart, including $10m for unannounced foreign inspections.

US FDA Staff Stability Should Be A Congressional Priority, Former Chief Of Staff Says

 
• By Derrick Gingery

Lawmakers should address FDA staff upheaval and help the agency “get back on track,” former agency Chief of Staff Elizabeth Jungman said, while CBER Director Vinay Prasad told staff he is asking ex-colleagues to return to the agency.

US FDA ‘Commissioner’s Voucher’ As Public Relations Tool

 
• By Michael McCaughan

NRx Pharma is trying to capitalize on the headlines about a new US FDA hyper-fast review program, illustrating that the lack of details in the FDA’s announcement is an opening for sponsors to try to grab some attention.

More from Agency Leadership